Abstract Rituximab, a monoclonal antibody against the CD20 molecule expressed on B cells, has revolutionized the treatment of B cell lymphomas. The use of rituximab significantly improves the long-term survival rates of lymphoma patients. However, there are still many patients who develop resistance to rituximab. Hence, the urgent need is enhancing the potency of anti-CD20 antibodies beyond that achieved with rituximab to provide effective therapies for more patients. Traditional studies about the killing mechanisms of rituximab are commonly based on optical microscopy, which cannot reveal the detailed situations due to the limit of 200-nm resolution. Quantitatively investigating the actions of rituximab at the nanoscale is still scarce. The advent of atomic force microscopy (AFM) provides a powerful and versatile platform for in situ investigating the nanoscale behaviors of individual live cells. The applications of AFM in life sciences in the past decade have yielded a lot of novel insights into cell biology and related diseases. In this article, the typical applications (e.g., ultra-microstructures, mechanical properties, and molecular recognition) of AFM in investigating the three killing mechanisms of rituximab at the nanoscale are summarized; the challenges facing AFM single-cell assay and its future directions are also discussed.
Introduction
Non-Hodgkin's lymphoma is the most common hematological cancer in adults, and about 85 % of non-Hodgkin's lymphomas in adults are of B cell origin [1] . Rituximab, the first monoclonal antibody drug approved by USFDA in 1997, heralded a new era of combined immunochemotherapy for the treatment of malignant lymphomas [2] . Rituximab is a chimeric monoclonal antibody (incorporating human immunoglobulin G1 heavy-chain sequences and murine immunoglobulin variable regions) that recognizes the human CD20 antigen [3] . CD20 is a tetraspanning membrane protein that is found on mature B cells, including >90 % of B cell lymphomas, but is absent from haematopoietic stem cells, plasma cells, and non-lymphoid tissue [4] . Hence, normal B cells are able to regenerate after the rituximab treatment and return to pretreatment levels within several months or even years [5] . In vitro studies have shown that the binding of rituximab to the CD20 on the lymphoma cell can cause the lysis of lymphoma cell via three mechanisms (as shown in Fig. 1 ) [6, 7] : programmed cell death (PCD), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular cytotoxicity (ADCC). Rituximab achieved unprecedented success in the clinical practice of lymphoma treatment: the use of rituximab (especially when combined with chemotherapy) can significantly improve the response rates and long-term remissions of B cell lymphoma patients [8] . Despite this success, there are still a proportion of patients who develop resistance to rituximab therapy [9] . Thus, the current challenge in lymphomatargeted therapy is enhancing the potency of anti-CD20 antibodies beyond that achieved with rituximab to provide effective therapies for these patients. To address this issue, we need to have a thorough understanding of the killing mechanisms of rituximab. Traditional biochemical studies about the actions of rituximab are commonly based on optical microscopy and often require the lysis of cells (e.g., the western blotting and polymerase chain reaction) [10] , which cannot reveal the nanoscale situations taking place on individual lymphoma cells. Quantitatively investigating the nanoscale physiological activities on individual lymphoma cells during the actions of rituximab is undoubtedly useful for us to better understand rituximab.
The advent of atomic force microscopy (AFM) provides an exciting tool for in situ investigating the nanoscale physiological activities on individual live cells [11] due to its unique advantages, including it can work in liquids, it has nanometer spatial resolution, and it is label-free. Besides imaging the surface topography of cells, AFM can acquire multiple parameters that reflect the physiological states of cells [12, 13] , e.g., cellular mechanics, molecular mechanics, energy dissipation, deformation, adhesion force, and molecular recognition. In the past decades, a large number of scholars have applied AFM to investigate related biological issues at the nanoscale, yielding a lot of novel insights into cell/molecular biology [14, 15] and certain diseases such as cancer [16] . We have used AFM to systematically investigate the three killing mechanisms of rituximab by visualizing and quantifying the cellular changes (including ultra-microstructures, mechanical properties, and molecular recognition) at the nanoscale. In this article, based on our previous studies, the progress of applying AFM to reveal the nanoscale cellular dynamics on individual lymphoma cells during the actions of rituximab's three killing mechanisms is summarized; the challenges and future directions of AFM single-cell assay are then discussed.
PCD Mechanism
Imaging the ultra-microstructures of living cells is one of the basic applications of AFM in life sciences. Currently, the studies of AFM living cell imaging are commonly performed on adherent cells [17, 18] or microbial cells [19, 20] . Adherent cells can naturally grow and spread on the substrate (e.g., glass slide and Petri dish); thus, we can directly perform AFM scanning on them without extra immobilization. Microbial cells are small and have stiff cell wall; thus, we can obtain highresolution AFM images on them with the immobilization of porous polymer membrane or poly-L-lysine electrostatic adsorption [21] . Mammalian suspended cells are soft and have large size, causing the porous polymer membrane method or pure electrostatic adsorption unsuitable. In order to observe the changes of nanostructures on living lymphoma cells (a type of human suspended cell) during the rituximab's PCD mechanism, we have developed an immobilization method combining micro-fabricated pillar's mechanical trapping and poly-L-lysine electrostatic adsorption [22, 23] , as shown in Fig. 2 . Pillar arrays were fabricated by photolithography on a silicon substrate (the height is 525 μm, and the diameter is 100 mm). The diameter of the micro-fabricated patterned pillars is 10 μm, and the height of pillars is 5 μm. The distance between two adjacent pillars is 10 μm. Figure 2a is a SEM image of the micro-fabricated pillars. After coating the chip with poly-L-lysine, lymphoma cell suspensions were then dropped onto the chip. Figure 2b is the AFM amplitude image of a living lymphoma cell trapped in the pillars. Imaging experiments were performed using the silicon nitride probe (type: DNP-S, purchased from Bruker Company, Santa Barbara, CA, USA), whose nominal spring constant was 0.12 N/m. In order to decrease the scrape effect caused by the scanning tip, images were obtained at tapping mode. The driving frequency was ∼9 kHz. The scanning rate was 0.3∼0.5 Hz. The scan line was 256, and the sampling point was also 256. The four pillars around the cell can help the cell to withstand the lateral force exerted by the scanning tip, while the poly-L-lysine on the substrate can absorb the cell vertically. Via the horizontal and vertical immobilization, we can obtain the AFM images of living lymphoma cells (Fig. 2b) . Based on the presented immobilization method, we then investigated the dynamical changes of cellular ultra-structures after the stimulation of rituximab. Figure 2c , d shows the changes of cellular nanostructures of a lymphoma cell after the stimulation of 0.2 mg/mL rituximab. From the AFM images, we can see that the cell surface became more corrugated Fig. 1 The three killing mechanisms of rituximab [6] . The binding of rituximab to the CD20 on the lymphoma cell can directly induce the programmed cell death (PCD) of the lymphoma cell. Besides, the binding can trigger the classical pathway of complement-dependent cytotoxicity (CDC). The final products of CDC are the membrane attack complexes (MACs), which lead to the lysis of the cells. After the binding of rituximab to CD20 on the lymphoma cell, the Fc portion of rituximab can bind to the Fc receptors on the surface of effector cells (e.g., NK cell and macrophage) and these effector cells can then attack the target cells (e.g., NK cells release cytotoxin to kill the cell and macrophages kill the cell via phagocytosis). Reprinted with permission from [6] . Copyright 2015 The Biophysical Society of China after the stimulation. When the concentration of rituximab increased to 0.5 mg/mL (Fig. 2e, f) , we can see that some obvious tubercles appeared on the cell surface (denoted by the arrows in Fig. 2f ). The AFM images evidently showed that the stimulation of rituximab could result in the significant changes of cellular nanostructures on the cell surface.
Cellular mechanical properties play an important role in regulating the cellular physiological activities. For example, during the process of tumor metastasis, circulating cancer cells should pass through several obstacles (e.g., basement membrane, extracellular matrix, and blood vessel wall), and whether the cancer cell can successfully metastasize largely depends on the mechanical properties (e.g., deformability and adherence) of the cancer cell [24, 25] . Pathological changes inside the cell can result in the changes of cellular mechanical properties; for example, cancer cells are softer than their normal counterparts [16, 26] . In order to investigate the role of cellular mechanical properties in the rituximab's PCD mechanism, we quantified the changes of cellular mechanical properties after the stimulation of rituximab. AFM measures the cellular Young's modulus by performing indenting experiments on the surface of cells. During the indentation process, force curves are recorded. By fitting the force curves with adequate theoretical models (the most commonly used models are Hertz model and Sneddon model [13] ), the Young's modulus of cells is obtained. In our experiments, in order to make the results comparable, all force curves were recorded at the same loading rate (240 nN/s). The ramp size of force curves was 2 μm. The maximal force applied on the cells was 20 nN. The type of the AFM probe was DNP-S (Bruker Company, Santa Barbara, CA, USA) whose tip was pyramidal. Thus, the Sneddon model was applied to obtain the cellular Young's modulus (Hertz model is used for sphere tip). Figure 2g shows the changes of Young's modulus of lymphoma cells after the stimulation of rituximab with different concentrations. After the stimulation of 0.2 mg/mL rituximab, the Young's modulus of lymphoma cell decreased from 196 to 183 kPa. After the stimulation of 0.5 mg/mL rituximab, the Young's modulus of lymphoma cell decreased from 234 to 175 kPa, showing that rituximab could induce the softening of lymphoma cells. For control, the Young's moduli of lymphoma cells stimulated by 0.5 mg/mL human IgG were measured, and the results showed that the Young's modulus of lymphoma cells kept unchanged. Human IgG has no biological effects on lymphoma cells, and hence, the stimulation of human IgG does not cause the changes of cellular mechanical properties. The stimulation of rituximab can activate the apoptosis pathway of lymphoma cell [6, 7] , which then results in the nanoscale changes (cellular ultra-microstructures and mechanical properties) of lymphoma cells, improving our understanding of rituximab's PCD mechanism at the nanoscale.
CDC Mechanism
During the CDC mechanism, the binding of rituximab to the CD20 of lymphoma cell can activate the classical pathway of complement-mediated cytotoxicity, which ultimately leads to the lysis of lymphoma cell by forming membrane attack complexes (MACs) on the cell surface [7] . However, due to the limit of 200-nm resolution, traditional optical microscopy cannot reveal the dynamic developments of MACs on the cell Fig. 2 Changes of cellular nanostructures and mechanical properties during the PCD mechanism of rituximab revealed by AFM [22, 23] . a SEM image of the micro-fabricated pillars. b AFM amplitude image of a living lymphoma cell trapped in the pillars. c, d AFM amplitude images of the same local area on a lymphoma cell before (c) and after (d) the stimulation of 0.2 mg/mL rituximab. The inset in c is the AFM amplitude image of the whole cell. e, f AFM amplitude images of the same local area on a lymphoma cell before (e) and after (f) the stimulation of 0.5 mg/mL rituximab. The inset in e is the AFM amplitude image of the whole cell. g Changes of cellular Young's modulus after the rituximab stimulation. a, b were reprinted with permission from [22] . Copyright 2010 Elsevier Inc. c-f were reprinted with permission from [23] . Copyright 2012 Editorial office of Acta Physico-Chimica Sinica surface during the process of rituximab-induced CDC mechanism. In order to explore how the CDC mechanism alters the cells at the nanoscale, we have applied AFM to visualize and quantify the dynamics of cellular nanostructures and cellular mechanical properties during the rituximab-induced CDC process [27] , as shown in Fig. 3 . Lymphoma Raji (a Burkitt's lymphoma cell line) cells were immobilized to the poly-L-lysine-coated glass slide and then fixed by 4 % paraformaldehyde. AFM images were obtained at contact mode. Both AFM height images and deflection images were recorded. The type of probe used was MLCT (purchased from Bruker Company, Santa Barbara, CA, USA) whose nominal spring constant was 0.01 N/m. The scan rate was 0.5 Hz. The scanning line was 256, and the sampling point for each scanning line was also 256. Figure 3a -f shows the AFM images of local areas on the lymphoma cells. The AFM imaging results distinctly showed that the CDC mechanism can be divided to three stages. At the initial stage ( Fig. 3a, b) , micro-pores occurred on the cell surface (denoted by the arrows). As CDC mechanism progresses, the pores became larger and cytoplasm began escaping from the cell (Fig. 3c, d) . Finally, the cell became flat and membrane debris left (Fig. 3e, f) . The changes of cellular nanostructures were due to the CDC effect [27] . During the CDC mechanism, MACs are formed on the cell surface. Water molecules can freely enter into the cell membrane via the MAC pores; thus, the shear effect of the flushing fluid can make the pores become larger. As the pores further became larger, intracellular structures (e.g., cytoplasm and organelle) then escaped from the cell. Finally, the cell collapsed and only membrane debris left.
By applying AFM indenting technique, the changes of cellular Young's modulus during the process of rituximabinduced CDC mechanism were measured, as shown in Fig. 3g . The type of the probe was MLCT, and the cantilever with nominal spring constant 0.01 N/m was used for indenting experiments. Force curves were obtained at the central areas on the cell surface. All force curves were obtained at the same loading rate (40 nN/s), and the maximal loading force was 10 nN. The Young's moduli of lymphoma Raji cells in three situations (before treatment, after treatment without CDC, and after treatment with CDC) were measured. The results (Fig. 3g) distinctly showed that during the process of CDC, cellular Young's modulus firstly decreased and finally increased. The Young's modulus of Raji cells measured here was significantly less than that in Fig. 2 . This is due to several factors. The first factor is the difference of loading rates. The loading rate in Fig. 2g (240 nN/s) was significantly larger than the loading rate in Fig. 3g (40 nN/s) . Li et al. [26] have shown that increasing the loading rate can cause the larger Young's modulus measured from the force curves. Thus, the larger loading rate in Fig. 2g could result in larger Young's modulus. The second factor is the difference of tip. The probe used in Fig. 2g was DNP-S whose tip radius was 10 nm, while the probe used in Fig. 3g was MLCT whose tip radius was 20 nm. This means that the contact areas in Fig. 2g was much smaller, resulting in that the larger measured Young's modulus. Besides, the type of AFM used in Fig. 2g was Dimension 3100 and the type of AFM in Fig. 3g was Bioscope Catalyst. Although both of these two types of AFM were produced by Bruker Company, they are still different in several facets (e.g., controller and hardware), and this difference may also influence the cellular mechanical property measurements. In fact, we keep in mind that it is difficult to measure the absolute values of cellular Young's modulus as they are highly affected by several factors (e.g., theoretical model, substrate, tip geometry, loading rate, temperature, experimental conditions, indenting parameters, the position, and time of poking [28] [29] [30] ). Thus, we maintain the indenting experimental conditions identical to measure the cellular Young's modulus values and analyze their relative changes. Under the identical conditions, the Young's modulus data could be compared with each other. Altogether, the results in Fig. 3 indicated that AFM can reveal the nanoscale dynamical changes during cellular physiological activities, improving our understanding of rituximab's CDC mechanism. The significance is that we can discern the different stages of CDC process by simply monitoring cellular nanostructures and mechanical properties via AFM. This will avoid the serious flaw of traditional fluorescence staining (the fluorescence labeling can inevitably alter the natural structures and functions of cells) and may help us to develop novel methods for drug screening and cancer diagnosis.
ADCC Mechanism
The ADCC mechanism of rituximab involves several types of effector cells, such as macrophages, granulocytes, and NK cells [31] . Until now, the exact contribution of these effector cells in the practical outcome remains unclear. There has been a tendency within the field to believe that NK cells are the most potent effectors according to the results in vitro, but some scholars have proposed that perhaps in vivo macrophages are much more important [7] . In order to explore the nanoscale situations taking place in phagocytosis, we have used AFM to visualize the quantification of the dynamical changes in cellular nanostructures and mechanical properties during the process of rituximab-mediated macrophage phagocytosis against lymphoma cells [32] , as shown in Fig. 4 .
Macrophage RAW 264.7 cell line was used. Raji cells were fluorescently labeled with CFSE molecules and coated by rituximab. Raji cells were then incubated with macrophages for 3 h at 37°C. After the co-incubation, cells were chemically fixed by 4 % paraformaldehyde. Images were obtained at contact mode in PBS. The nominal spring constant of the probe cantilever was 0.01 N/m. The scan rate was 0.5 Hz. The scan line and the sampling point were 256. Both the height image and deflection image were recorded. Figure 4a -f shows the dynamical changes of riuximabmediated macrophage phagocytosis against lymphoma Raji cell. Only the AFM deflection images were shown. From AFM images, we can clearly see the detailed contact situations between lymphoma cell and macrophage. At the initial stage (Fig. 4a, b) , the lymphoma cell docked on the macrophage and the engulfing of the macrophage did not occur. Figure 4c, d shows that the macrophage opened its mouth to engulf the lymphoma cell, indicating the beginning of engulfing. Figure 4e , f shows that the macrophage has engulfed some portion of the lymphoma cell. We can see that the edge of lymphoma cell in Fig. 4f was not natural but looks artificial, which is caused by the convolution effect of AFM imaging [33] . We know that the AFM images essentially are the convolution results between AFM tip and specimen topography. For adherent cells, they can spread on the substrate and the changes of cell topography are smooth, resulting that the evolution effects are weak and we can get the natural cellular topography [34] . Lymphoma cell is a type of suspended cell which cannot spread on the substrate. The border areas between the cell edge and substrate are abrupt, resulting in the strong evolution effects, and thus, the images of cell edge look artificial. Traditional studies about the rituximab's ADCC mechanisms were based on ensemble results from many cells Fig. 4 Changes of cellular nanostructures and mechanical properties during the ADCC mechanism (macrophage phagocytosis) of rituximab revealed by AFM [32] . a-f AFM deflection images of a, c, e whole cells and b, d, f local areas (denoted by the squares) during the macrophage phagocytosis. g Changes of Young's modulus of macrophages after phagocytosis. Reprinted with permission from [32] . Copyright 2014 American Chemical Society [10] , indicating that detailed information at the single-cell level is scarce. Here, the results (Fig. 4a-f ) acquired by AFM clearly revealed the detailed cellular morphological changes during rituximab-mediated macrophage phagocytosis, which were complementary to the traditional ensemble results and useful for helping us to understand the ADCC mechanism. By indenting technique, the mechanical changes of macrophages during phagocytosis were quantified. The type of probe was MLCT, and the nominal spring constant of the cantilever was 0.01 N/m. For each cell, 50 force curves were recorded on different points at the central area of the cell. All force curves were obtained at the same loading rate (40 nN/s). Figure 4g shows the changes of Young's modulus of living macrophages after engulfing the lymphoma cell during the phagocytosis. The results indicated that after engulfing the lymphoma cell, macrophage became stiffer (Young's modulus increased from ∼2 to ∼3 kPa). The loading rate of Fig. 4g was the same as the loading rate in Fig. 3g , and we can see that the cellular Young's modulus values were of the same order of magnitude. When macrophage phagocytosis was activated, a rapid accumulation of F-actin and associated proteins in the periphagosomal region occurred. We know that cytoskeletons determine the cellular mechanical properties [35] . Hence, the reorganization of actin and associated proteins results in the subsequent changes of cellular Young's modulus.
Rituximab Actions on Patient Tumor Cells
Current studies about the mechanisms of anti-CD20 antibodies were commonly performed on cell lines cultured in vitro. Though allowing for the rapid, rigorous, and focused evaluation of specific mechanisms of action, the conditions we have available in the laboratory vary significantly from the real-world clinical environment [8] . The huge difference between in vitro 2-D environment and in vivo 3-D environment can result in the significant changes in cell structures and functions. As we move into an era of personalized medicine, it will be increasingly important for us to develop closer links between the laboratory and the clinic to enhance the potency of anti-CD20 antibodies [9] . Viewed from this aspect, directly investigating the behaviors of tumor cells from lymphoma patients will be of remarkable clinical impact. We have used AFM to probe the interactions between rituximab and CD20 on tumor cells prepared from clinical lymphoma patients under the fluorescence recognition of specific markers [5, [36] [37] [38] , as shown in Fig. 5 . The prepared clinical biopsy samples (such as bone marrow) contained both tumor cells and healthy cells; thus, the prerequisite is identifying the tumor cells from the healthy cells. Traditional methods for isolating lymphoma cells from the clinical biopsy samples are commonly based on the labeling of CD19 and CD20 molecules [39, 40] . However, normal B cells also express CD19 and CD20. Hence, the results included the behaviors of normal B cells and tumor B cells. We are interested in the behaviors of tumor B cells, because their behaviors are directly related to the treatment outcomes. Recent studies have shown that the receptor tyrosine kinase-like orphan receptor 1 (ROR1) is exclusively expressed on B cell leukemia and lymphomas but not on normal B cells and other healthy tissues [41] [42] [43] . Hence, ROR1 is an adequate marker for identifying tumor B cells from lymphoma patients. Figure 5a is the overlay of ROR1 fluorescence image and bright field image of the bone marrow sample from a clinical B cell lymphoma patient. We can see that one cell exhibited bright fluorescence (denoted by the red square), indicating that it was a tumor cell. (Fig. 5g) , we can clearly see that the size of tumor cell (9.77 μm) was significantly larger than that of normal cells (6.95 μm). We know that when a normal cell transforms into a cancer cell, its structures and functions will change remarkably, e.g., the nuclear volume becomes larger and irregular [44, 45] . These intracellular changes may result in that the size of tumor cells was larger than normal cells.
By applying AFM single-molecule force spectroscopy (SMFS) technique, we measured the interaction force between rituximab and CD20 on the patient tumor cell. The principle of SMFS is recording force curves on cell surface using the functionalized probe carrying specific ligands which can specifically recognize the receptors on the cell surface [46] . During the approaching-retracting cycle, if the ligand on the tip binds to the receptor on the cell surface during the contact between tip and cell, then the ligand-receptor pair is stretched when the tip retracts from cell surface. When the pulling force exerted by the cantilever is larger than the binding force between a ligand and a receptor, the pair ruptures and a specific peak occurs in the retract curve. According to the covalent coupling method [36, 47, 48] , rituximab molecules were linked to the surface of AFM tip using NHS-PEG2000-MAL linkers. Briefly, the silicon nitride tips were firstly coated with a layer of NH 2 by aminopropyltriethoxysilan (APTES) and N,N-diisopropylethylamin by using a vapor deposition method. Then rituximab molecules were treated by N-succinimidyl 3-(acetylthio) propionate (SATP) to form thiol function groups. The NHS end of the linker can covalently interact with NH 2 on the tip, and the MAL end of the linker can interact with thiol groups. The covalent bonds (1-2 nN) are at least ten times stronger than typical receptor-ligand bonds (∼20-200 pN) [49, 50] . Thus, during the retraction process of SMFS, the CD20-rituximab bonds firstly ruptured. In order to validate that whether rituximabs had been linked to AFM tip, we performed secondary antibody fluorescence labeling experiments. Figure 5b is the fluorescence image of a functionalized probe. We can see that the probe exhibited bright fluorescence, indicating that there were rituximabs on the AFM tip. Figure 5h is a typical force curve recorded on the tumor B cell using rituximab-conjugated tip. We can see a specific molecular unbinding peak in the retract curve (denoted by the green arrow). The inset in Fig. 5h is the enlarged view of the specific unbinding peak. The peak reflected the unbinding process of a CD20 and a rituximab. By recording 16×16 force curves at local area (500×500 nm 2 ) on the tumor cell, gray maps reflecting the distributions of CD20 were constructed (Fig. 5i) . The bright and gray pixels in the maps correspond to the CD20s with different binding affinities. For contrast, gray maps on normal cells (red blood cells) were also recorded, as shown in Fig. 5j . We can see that few gray pixels were in the maps obtained on normal cells, and this is because normal cells (red blood cells) do not express CD20. The molecular distribution gray maps (Fig. 5i) showed that the distribution of CD20s on the cell surface was not uniform. We know that cell membranes are segregated into heterogeneous areas by lipid rafts which are fluctuating nanoscale assemblies of sphingolipid, cholesterol, and proteins [51] . Hence, the heterogeneity of cell membrane may result in the non-uniform distribution of CD20 on the tumor cell. Compared with the studies on cells cultured in vitro, the significance of investigating the physiological activities directly on tumor cells prepared from patients is that the results are closer to the real situations in vivo, and thus, we can obtain more valuable information which is useful for us to better understand drugtarget interactions and design drugs. force curve with a specific molecular unbinding peak (denoted by the green arrow) recorded on tumor B cells. The inset is the enlarged view of the peak. i Molecular distribution gray maps on tumor cells. j Distribution gray maps on normal cells (red blood cells). a, c-f, and h-j were reprinted with permission from [37] . Copyright 2013 Elsevier, Inc. b was reprinted with permission from [36] . Copyright 2013 John Wiley & Sons, Ltd
Conclusions and Outlook
In the past 20 years, the targeted therapy based on rituximab has revolutionized the treatment of CD20+ lymphomas, making a giant stride towards personalized medicine. The current challenge in lymphoma-targeted therapy is how to enhance the potency of anti-CD20 antibodies to provide effective therapies for patients who develop resistance to rituximab. Several novel anti-CD20 antibodies (e.g., ofatumumab, tositumomab, and obinutuzumab) have been developed and used for clinical trials; however, it is disappointing that none of the newer antibodies have been shown to be clinically more effective than rituximab in a direct comparison [3] . Due to the complexity of rituximab actions (e.g., it involves three killing mechanisms, it requires the participation of effector cells and complement proteins, and it is often combined with chemotherapy drugs in clinical practice), the in vivo mechanisms of rituximab are still unclear, hindering the development of newer anti-CD20 antibodies. A better understanding of rituximabmediated killing mechanisms is essential for us to develop more effective therapeutic agents with enhanced efficacies beyond that achieved with rituximab [52] .
In this paper, we summarized applying AFM to investigate rituximab actions at the nanoscale based on our previous studies. AFM imaging and mechanical analysis clearly revealed the dynamical changes of nanoscale cellular structures and cellular mechanical properties during the three killing mechanisms of rituximab. Besides, the nanoscale CD20-rituximab interactions were quantified directly on tumor B cells prepared from the clinical lymphoma patients via SMFS based on the fluorescence recognition of specific surface markers. Traditional studies about the drug actions are based on the bulk measurements which are performed on purified molecules from many cells or directly on many cells. These studies essentially provide averaged information of the ensemble population [53] . Knowledge about rituximab actions at single-cell and single-molecule levels is scarce. Especially in the coming era of personalized medicine, exactly diagnosing the disease states for each patient is the prerequisite of planning clinical therapy. This requires us to thoroughly understand the drug actions. Investigating drug actions from multiple facets can undoubtedly help us to better understand the underlying mechanisms that regulate the drug's killing effects. AFM can in situ visualize the dynamic changes of cellular ultramicrostructures and quantify the real-time alterations of cellular mechanical properties directly on individual living cells, which is inaccessible by traditional biochemical methods. The results obtained by AFM not only provide novel insights into cellular behaviors and related diseases at the nanoscale but also allow us to explore the life mysteries from the perspective of label-free trials. By combing AFM indenting technique with clinical breast cancer therapy, a recent study by Plodinec et al. [16] has shown that cellular mechanical property is an effective label-free biomarker that can be used to discern the different stages of cancer development (normal tissue, benign lesion, and invasive cancer), clinically demonstrating the practical significance of AFM single-cell assay. In the future, by monitoring the dynamic changes of cellular mechanical properties after the stimulation of drugs, we can develop novel methods which can be used to evaluate drugs (these drugs can alter tumor cell's mechanical properties to hinder the progression of tumor cell [54] ) or predict the efficacies of therapeutic agents (this will help us to recognize the patients who will potentially benefit from the therapy).
On the other hand, current studies of cellular and molecular behaviors are commonly performed on cell lines cultured in vitro which are quite different from the cells in human body. For example, studies of rituximab mechanisms of action often utilize tumor cell lines that have been selected based on their ability to grow rapidly in vitro and sometimes their relative sensitivity to therapy [8] . Thus, these studies may not faithfully reflect properties of the same molecules (cells) in vivo [55] , resulting in a large gap between laboratory studies and clinical environment. Viewed from this aspect, directly investigating the physiological activities on cancer cells from clinical patients can improve our understanding of the cancers. By recognizing the tumor cells based on the fluorescence labeling of tumor cell surface specific marker, we have developed a method to quantify the individual receptor-ligand interactions (including measuring the molecular binding affinity and mapping the distributions of membrane proteins on cell surface) directly on patient tumor cells using AFM single-molecule force spectroscopy [36] [37] [38] , not only improving our understanding of CD20-rituximab interactions but also providing a new idea to investigate drug-target interactions in near in vivo conditions. In future studies, we plan to apply the established methods to investigate the rituximab actions on more lymphoma patient tumor cells (e.g., monitoring the changes of cellular mechanical properties after the drug stimulation and analyzing the difference of drug-target interactions between different lymphoma sub-types), exploring the potential significance of AFM single-cell assay in clinical lymphoma therapy. Altogether, the achievements of AFM in the past decades have demonstrated its great potential in accessing the cellular activities at the nanoscale and provide new ideas to address the related biological and medical issues. However, there are several challenges that need to be addressed to further improve the current studies of AFM single-cell assay.
The first challenge is to improve the spatial resolution and temporal resolution of AFM [13] . Currently, high-resolution AFM imaging has been mainly limited to microbial cells which have well-defined and stiff cell envelope [56] . The spatial resolution of AFM imaging on mammalian cells is 50∼100 nm due to the soft, dynamic, and highly heterogeneous nature of the cell surface [11] , causing that we cannot visualize the single molecules on the surface of living mammalian cells. For improving the spatial resolution of AFM imaging, on the one hand, we can develop novel immobilization methods to inhibit the movement of cell membrane; e.g., we can attach live cells within a thin film having small pores of ∼100 nm diameter [57] . Cell surfaces exposed to the pores are rigid, and therefore, we may obtain high-resolution images of the local areas on the cell surface. On the other hand, we can improve the AFM imaging mode; e.g., inspired by scanning ion conductance microscopy (SICM), we may develop non-contact AFM imaging mode [58] . At the noncontact mode, AFM tip does not contact the cell surface (avoiding the deformations of cell surface caused by AFM), and thus, it may improve the spatial resolution of imaging. At present, obtaining one AFM image of living cells often requires several minutes, which is significantly larger than the time scale at which cellular dynamical activities occur [11] . Although high-speed AFM has gained great achievements in the past few years, it is mainly limited to isolated proteins attached to flat substrate [57, 58] or certain types of cells (e.g., microbial cells [59] and lens cells [60] ). In order to make the high-speed AFM suitable to living mammalian cells which are more complex than microbial cells (e.g., soft and rough cell surfaces and large cell size), technical and conceptual obstacles (e.g., large-size scanners) are needed to be overcome [61] .
The second challenge is to improve the throughput of AFM experiments. Currently, in the process of AFM single-cell assay, the operator controls the AFM tip to move to the target cell to perform manipulations (e.g., scanning and recording force curves) under the guidance of optical microscopy (or fluorescence [36] ). After the manipulations are finished, the operator controls AFM tip to another cell. This manualdependent process leads to a very low throughput (the time of handling one cell is often several minutes) [13, 62, 63] . In practice, in order to obtain statistically significant results, we need to perform experiments on many cells, and this will results in heavy workloads. Hence, the low throughput has become one of the main factors hindering the practical applications (e.g., drug screening and efficacy assessing) of AFM. In order to improve the throughput, on the one hand, we can introduce automation technique to reduce the manual intervention, e.g., automatically moving AFM tip to the cell by recognizing the cells using image processing technique [64] . On the other hand, we may recognize the representative cells in the sample by combining biochemical methods [65] . Performing measurements on representative cells will improve the experimental efficiency. If fully automated AFM measurements can be achieved, then they can be applied to drug screening (e.g., automatically monitoring the changes in cellular nanostructures and mechanical properties after drug stimulation) [13] .
The third challenge is to standardize the procedure of AFM measurements. Currently, the outcomes of AFM experiments are dependent on several factors, e.g., the quality of the sample and tip-preparation procedures, the quality of data recorded, and the accuracy of data interpretation [11] , which are closely related to the experience of the operator. Especially for the experiments of molecular recognition, it requires the functionalization of the cantilever (e.g., linking molecule, virus, or cell to the cantilever [66, 67] ), which is labor-intensive and needs specific expertise. Hence, establishing simple standardized protocols for AFM experiments (including tip/ sample preparation, instrumental preparation, parameter calibration, data recording, data interpretation, and data analysis) will not only facilitate the newcomers to quickly grasp this technology but also will reduce the artificial effects. The standardization of AFM measurements will allow that the results obtained by different groups can be compared with each other [68] .
In summary, the achievements of investigating the cellular behaviors at the nanoscale in the past decade have demonstrated the invaluable role of AFM in life sciences and medicine. In the future, as the challenges described above are gradually being resolved, the performance of AFM will continue to be improved and this will promote its applications in addressing more related biomedical issues. The further applications of AFM will yield more and more novel insights into the underlying mechanisms that guide the cellular physiological activities, potentially having profound impact on diverse fields such as drug research, disease diagnosis, and efficacy prediction.
